Vanguard Global Advisers
PAVM icon

Vanguard Global Advisers’s PAVmed PAVM Stock Holding History

Vanguard Global Advisers’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61
Closed -$619 – 3711
2026
Q1 		$619 Buy
+61
New +$577 ﹤0.01% 3654

Other funds holding PAVM

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Global Advisers's PAVM Position: Q2 2026 in Review

Vanguard Global Advisers sold out of PAVmed (PAVM) in Q2 2026, closing a stake of 61 shares — an estimated $619 sold.

Vanguard Global Advisers first reported a position in PAVM in Q1 2026 and held it in 1 quarter. The position peaked at $619 in Q1 2026. 19 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.

  • Vanguard Global Advisers reported no remaining PAVmed position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 61 PAVmed shares in Q2 2026, an estimated $619.
  • Vanguard Global Advisers first reported a position in PAVmed in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's PAVmed position peaked at $619 in Q1 2026.
  • 19 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.